Results from the Randomized Phase III DREAMM-7 Study of Belantamab Mafodotin (belamaf) + Bortezomib, and Dexamethasone (bvd) Vs Daratumumab, Bortezomib, and Dexamethasone (dvd) in Relapsed/refractory Multiple Myeloma (RRMM).
JOURNAL OF CLINICAL ONCOLOGY(2024)
关键词
Diagnosis Criteria
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要